

To: (10)(2e); (10)(2e)@minvws.nl; (10)(2e); (10)(2e)@minvws.nl
From: (10)(2e)
Sent: Fri 8/28/2020 1:22:27 PM
Subject: Fwd: COVID-19 rapid antigen test BinaxNOW URGENT question
Received: Fri 8/28/2020 1:22:30 PM
Recommendation: [Develop a Protocol for In Country Evaluation Panbio™ COVID-19 Ag test 1.1.pdf](#)

Hartelijke groet,

(10)(2e)

Begin forwarded message:

From: "(10)(2e)" <(10)(2e)@umcutrecht.nl>
Subject: FW: COVID-19 rapid antigen test BinaxNOW URGENT question
Date: 28 August 2020 at 15:04:47 CEST
To: "(10)(2e)" <(10)(2e)@umcutrecht.nl>

Aanvullende relevante info Abbott

Gr

(10)(2e)

Van: (10)(2e) <(10)(2e)@abbott.com>
Verzonden: vrijdag 28 augustus 2020 14:59
Aan: (10)(2e); (10)(2e)
CC: (10)(2e); (10)(2e)
Onderwerp: RE: COVID-19 rapid antigen test BinaxNOW URGENT question

Dear (10)(2e)

It was a pleasure to be in touch with you today.

To summarize our conversation and in addition to the docs that you received, you could see bellow key points regarding our Panbio Rapid tests :

- The product is CE marked, and it is available now. (10)(1c)
- Worldwide pricing : We want to propose an accurate, safe and easy to use rapid test, (10)(1c)
- Sample : Nasopharyngeal swabs
- Performance : The test provide very good performance for symptomatic patient between 0 and 7 days.
- Storage : room temperature
- (10)(1c)
- Evaluation : Attached, our recommendations to evaluate the product. If you want to evaluate locally the product, I need to receive a letter signed from government with quantities requested. I supposed that It will be easy to manage next week.

Please, feel free to ask me any questions.

Best regards



(10)(2e)

Abbott Rapid Diagnostics SAS Mobile : + (10)(2e)
Parc Burospace Bureau : (10)(2e)
Route de Gisy, Bât 6
91570 Bièvres, France (10)(2e) @abbott.com

This communication may contain information that is proprietary, confidential, or exempt from disclosure. If you are not the intended recipient, please note that any other dissemination, distribution, use or copying of this communication is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer.

De : (10)(2e) <(10)(2e)@abbott.com>
Envoyé : vendredi 28 août 2020 13:38
À : (10)(2e) <(10)(2e)@umcutrecht.nl>
Cc : (10)(2e) <(10)(2e)@abbott.com>; (10)(2e) <(10)(2e)@abbott.com>
Objet : FW: COVID-19 rapid antigen test BinaxNOW URGENT question

Hi (10)(2e)

Attached, some documentation regarding our Rapid test for Panbio Ag Covid Testing.

This test is very similar to the Binax product. (10)(1c)

The test is CE marked and could be available for Netherlands.

My colleague (10)(2e) will give you a call as well.

Regards

(10)(2e)



(10)(2e)

(10)(2e)

Abbott
Avenue Einstein 14
1300 Wavre
Belgium

O: (10)(2e)

M: (10)(2e)

(10)(2e) @abbott.com

This communication may contain information that is proprietary, confidential, or exempt from disclosure. If you are not the intended recipient, please note that any other dissemination, distribution, use or copying of this communication is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer.

De informatie opgenomen in dit bericht kan vertrouwelijk zijn en is uitsluitend bestemd voor de geadresseerde. Indien u dit bericht onrecht ontvangt, wordt u verzocht de inhoud niet te gebruiken en de afzender direct te informeren door het bericht te retourneren. Het Universitair Medisch Centrum Utrecht is een publiekrechtelijke rechtspersoon in de zin van de W.H.W. (Wet Hoger Onderwijs en Wetenschappelijk Onderzoek) en staat geregistreerd bij de Kamer van Koophandel voor Midden-Nederland onder nr. 30244197.

Denk s.v.p aan het milieu voor u deze e-mail afdrukt.

This message may contain confidential information and is intended exclusively for the addressee. If you receive this message unintentionally, please do not use the contents but notify the sender immediately by return e-mail. University Medical Center Utrecht is a legal person by public law and is registered at the Chamber of Commerce for Midden-Nederland under no. 30244197.

Please consider the environment before printing this e-mail.